Britannia Pharmaceuticals, part of the STADA group, is a UK based pharmaceutical company. We specialise in innovative products for chronic and serious medical conditions, and in particular, the treatment of Parkinson’s disease. We are highly committed to improving the quality of life for People with Parkinson's disease. Our key product Apomorphine Hydrochloride (Brand names: APO-go, APOKYN, Apomine) is a treatment for Parkinson’s disease which is available in many markets through our Distribution or Licensing Partners. Additionally we have developed non-opiate based therapeutics to assist in opiate detoxification and withdrawal. We are actively looking to in-license marketed products for the UK, other parts of Europe and even for the US, ideally in Movement Disorders or Mental Health but also in speciality areas where expertise is required for infusions via portable pumps. We have the infrastructure and nurse care to support the home administration of this type of product. We will also consider late stage CNS/other specialist products either in phase 3 or in registration.